Which regulatory mechanism is responsible for the decrease in HMG-CoA reductase expression when intracellular cholesterol levels are elevated?

Explanation

## Transcriptional Regulation of Cholesterol Synthesis **Key Point:** SREBP (Sterol Regulatory Element Binding Protein) is a transcription factor that senses cellular cholesterol levels and directly controls the expression of HMG-CoA reductase and other cholesterol synthesis genes. **High-Yield:** When cholesterol is **abundant**, SREBP is **inactivated** (remains bound to the ER membrane), preventing transcription of HMG-CoA reductase. When cholesterol is **scarce**, SREBP is **activated** (released and transported to the nucleus), promoting HMG-CoA reductase gene expression. ## SREBP Regulatory Pathway ```mermaid flowchart TD A[Low cholesterol]:::outcome --> B[SREBP released from ER]:::action B --> C[SREBP translocates to nucleus]:::action C --> D[SREBP binds SRE in HMG-CoA reductase promoter]:::action D --> E[Increased HMG-CoA reductase transcription]:::outcome F[High cholesterol]:::outcome --> G[SREBP remains bound to ER<br/>via SCAP and Insig proteins]:::action G --> H[SREBP cannot enter nucleus]:::action H --> I[Decreased HMG-CoA reductase transcription]:::outcome ``` **Mnemonic:** **SREBP = Sterol-sensing Regulator of gene Expression — Binds Promoter** — High cholesterol = SREBP stays put (ER-bound); Low cholesterol = SREBP goes to nucleus. ## Multilevel Regulation of HMG-CoA Reductase | Level of Control | Stimulus | Effect | Timescale | | --- | --- | --- | --- | | **Transcriptional** | High cholesterol → SREBP inactivation | ↓ mRNA synthesis | Hours | | **Translational** | Cholesterol, oxysterols | ↓ mRNA stability | Hours | | **Post-translational (allosteric)** | Cholesterol, mevalonate | ↓ Enzyme activity | Minutes | | **Post-translational (covalent)** | Low energy (AMPK activation) | Phosphorylation → inactivation | Minutes | | **Protein degradation** | High cholesterol → ubiquitination | ↓ Enzyme protein | Hours | **Clinical Pearl:** This multi-level regulation ensures that cholesterol synthesis is tightly controlled. Statins work at the enzyme level (allosteric inhibition), but the cell compensates by upregulating SREBP and increasing HMG-CoA reductase gene expression — this is why combination therapy (statin + ezetimibe) is sometimes needed.